ZUG, Switzerland & DUBAI, United Arab Emirates–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and taiba Middle East, a leading rare disease company based in the United Arab Emirates and covering the Middle East region, announced today that they have formed a Distribution Agreement for both ONPATTRO® and GIVLAARI®, the first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1.
“The cooperation with taiba allows us to address the unmet medical needs of patients with rare diseases, particularly where those diseases have a higher regional prevalence. That is why it is so important that patients in the Middle East are not disadvantaged when it comes to accessing effective treatments,” said Brendan Martin, Vice President and Acting Head of Europe, Middle East & Africa, and Canada, Alnylam Pharmaceuticals. “taiba has a regional presence with operations in multiple Gulf states, and a proven track record of marketing and distributing medicines for rare diseases. Our collaboration marks an important first step in bringing our current and future therapies to those patients with urgent medical needs.”
Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States July 08, 2020 07:57 AM Eastern Daylight Time ZUG, Switzerland & DUBAI, United Arab Emirates–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and taiba Middle East, a leading rare disease company based in the United Arab Emirates and covering the Middle East region, announced today that they have formed a Distribution Agreement for both ONPATTRO® and GIVLAARI®, the first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1. “We are proud to collaborate with Alnylam in the Gulf states” Tweet this “The cooperation with taiba allows us to address the unmet medical needs of patients with rare diseases, particularly where those diseases have a higher regional prevalence. That is why it is so important that patients in the Middle East are not disadvantaged when it comes to accessing effective treatments,” said Brendan Martin, Vice President and Acting Head of Europe, Middle East & Africa, and Canada, Alnylam Pharmaceuticals. “taiba has a regional presence with operations in multiple Gulf states, and a proven track record of marketing and distributing medicines for rare diseases. Our collaboration marks an important first step in bringing our current and future therapies to those patients with urgent medical needs.” “We are proud to collaborate with Alnylam in the Gulf states,” said Saif Al Hasani CEO of the taiba Group. “Alnylam’s portfolio of ground-breaking medicines will enhance our rare disease portfolio and enable us to offer innovative treatments to patients. Those patients with hATTR amyloidosis and other rare diseases deserve to have the earliest possible access to novel new treatments. We look forward to making this a reality, beginning with ONPATTRO and GIVLAARI.”
The Agreement between Alnylam and taiba will initially cover the Gulf states, including the Kingdom of Saudi Arabia, Kuwait, Bahrain, Qatar, Oman and the United Arab Emirates. It includes ONPATTRO, approved in the European Union (EU) in August 2018 for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy; GIVLAARI, approved in the EU in March 2020 for the treatment of acute hepatic porphyria (AHP); and lumasiran, a late-stage investigational RNAi therapeutic for the treatment of Primary Hyperoxaluria Type 1 (PH1).
“We are pleased to partner with taiba to provide access to ARIKAYCE for appropriate patients in the Gulf Cooperation Council region,” said Neil Hughes, General Manager, Head of EMEA, for Insmed. “Taiba’s extensive experience in providing access to rare disease therapies in the Middle East makes it an ideal partner for Insmed as we expand our reach globally and serve patients with significant unmet needs.”
About ONPATTRO® (patisiran)
ONPATTRO is an RNAi therapeutic that was approved in the United States and Canada for the treatment of the polyneuropathy of hATTR amyloidosis in adults. ONPATTRO is also approved in the European Union, Switzerland and Brazil for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy, and in Japan for the treatment of hATTR amyloidosis with polyneuropathy. ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin (TTR). It is designed to target and silence TTR messenger RNA, thereby blocking the production of TTR protein before it is made. ONPATTRO blocks the production of TTR in the liver, reducing its accumulation in the body’s tissues in order to halt or slow down the progression of the polyneuropathy associated with the disease.
Over the last fifteen years taiba has earned a reputation as a regional leading company in rare diseases and currently represents leading multinational companies pioneer in their fields such as Alnylam, Aegerion, Biomarin, Genzyme, Lucane, Veloxis, Vertex etc.
Sources:
https://www.ema.europa.eu/en/medicines/human/EPAR/arikayce-liposomal
